Agenus Stock Drops 5.50 percent Amid Biotech Sector Decline
AGEN Stock | USD 3.32 0.04 1.19% |
About 70% of Agenus' investor base is looking to short. The analysis of the overall investor sentiment regarding Agenus Inc suggests that many traders are alarmed. Agenus' investing sentiment overview a quick insight into current market opportunities from investing in Agenus Inc. Many technical investors use Agenus Inc stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Agenus |
Agenus Inc. , a biotechnology company, saw its stock price plummet by 5.50, trading at 3.53 per share with a trading volume of 480,929 shares. The compa
Read at gurufocus.com
Agenus Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Agenus can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Agenus Fundamental Analysis
We analyze Agenus' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Agenus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Agenus based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Agenus is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Agenus Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Agenus stock to make a market-neutral strategy. Peer analysis of Agenus could also be used in its relative valuation, which is a method of valuing Agenus by comparing valuation metrics with similar companies.
Peers
Agenus Related Equities
LPTX | Leap Therapeutics | 7.28 | ||||
ADAP | Adaptimmune Therapeutics | 3.85 | ||||
PIRS | Pieris Pharmaceuticals | 2.60 | ||||
MREO | Mereo BioPharma | 1.58 | ||||
XFOR | X4 Pharmaceuticals | 0.45 | ||||
MDGL | Madrigal Pharmaceuticals | 1.78 | ||||
PDSB | PDS Biotechnology | 2.28 | ||||
EWTX | Edgewise Therapeutics | 2.58 | ||||
MRKR | Marker Therapeutics | 2.76 | ||||
AFMD | Affimed NV | 2.93 | ||||
TGTX | TG Therapeutics | 3.56 | ||||
VKTX | Viking Therapeutics | 4.97 | ||||
ADCT | ADC Therapeutics | 35.63 |
Check out Agenus Hype Analysis, Agenus Correlation and Agenus Performance. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agenus. If investors know Agenus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agenus listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.02) | Revenue Per Share 7.808 | Quarterly Revenue Growth 0.033 | Return On Assets (0.22) | Return On Equity (12.79) |
The market value of Agenus Inc is measured differently than its book value, which is the value of Agenus that is recorded on the company's balance sheet. Investors also form their own opinion of Agenus' value that differs from its market value or its book value, called intrinsic value, which is Agenus' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agenus' market value can be influenced by many factors that don't directly affect Agenus' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agenus' value and its price as these two are different measures arrived at by different means. Investors typically determine if Agenus is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agenus' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.